As part of our purpose to serve overlooked patients, we’re sharing that an FDA-approved ready-to-use oral solution for treating ADHD in adults and pediatric patients 6 years and older will be available mid-2026. #overlookedpatients #ADHD Learn more: bit.ly/4quaiHV
BREAKING NEWS: ACA Pharma Named Exclusive Distributor for Ferabright™ in Macau, Hong Kong, Singapore, Greater Bay Area & Mainland China
hashtag #overlookedpatients azurity.com/aca-pharma-named…
Even with multiple options for #hypertension, ~33M Americans still have high #bloodpressure despite treatment. Watch the @HCPLiveNews full interview with Paul Whelton, MD, here👉 bit.ly/4pmotPH
BREAKING NEWS: Azurity Pharmaceuticals Announces the Availability of JAVADIN™ (clonidine hydrochloride) Oral Solution #overlookedpatients #hypertension #innovation azurity.com/azurity-pharmace…
We're heading to Las Vegas, NV for the 2025 ASHP Midyear Clinical Meeting (December 8-10). Come visit us at Booth #654 to learn more about how Azurity is serving overlooked patients. #ASHP25 #OverlookedPatients
We're heading to Chicago, IL for the 2025 Radiological Society of North America annual meeting (Nov 30-Dec 4). Come visit us at Booth #3578 to learn more about how Azurity is serving overlooked patients. #RSNA25 #OverlookedPatients
Breaking News: Azurity Pharmaceuticals and Sebela Pharmaceuticals announced Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise. #overlookedpatients azurity.com/azurity-pharmace…
Innovation meets impact! Azurity Pharmaceuticals is excited to announce Ogilvy Health as our new PR and Marketing Agency of Record. Read more here: bit.ly/4p5CBwc #HealthcareMarketing #PR #BrandStrategy
Come visit us at CPHI Frankfurt stand 9.2F54 to learn more about how Azurity is serving overlooked patients! #overlookedpatients #Innovation #CPHI
BREAKING NEWS: Azurity Pharmaceuticals Announces FDA Approval of JAVADIN™ (clonidine hydrochloride) Oral Solution #overlookedpatients #hypertension #innovation
azurity.com/azurity-pharmace…
BREAKING NEWS: Azurity Pharmaceuticals Announces the FDA Approval of Ferabright™ (ferumoxytol injection), the First and Only Iron-Based Contrast Agent Indicated for Magnetic Resonance Imaging of the Brain #overlookedpatients #MRI
azurity.com/azurity-pharmace…





